Disease block
C50-C50 – Bösartige Neubildungen der Brustdrüse [Mamma]
- Chapter II: Neubildungen
48Decisions
85Patient groups
Added benefit by patient group
- Major1
- Considerable12
- Minor14
- Non-quantifiable3
- Not proven53
- Lesser benefit2
Diseases in this disease block
- C50 Bösartige Neubildung der Brustdrüse [Mamma] 48 decisions
Decisions, newest first
Each decision lists only the patient groups coded with a disease in this disease block.
- 2026-09-03InluriyoImlunestrantNon-quantifiable: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
- 2026-08-20VerzeniosAbemaciclibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2026-02-19ItovebiInavolisibConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2025-11-20DatrowayDatopotamab deruxtecanNot proven: 3 of 3 patient groups
- 2025-10-16EnhertuTrastuzumab deruxtecanMinor
- 2025-10-16AugtyroRepotrectinibNot proven: 2 of 2 patient groups
- 2025-06-05KisqaliRibociclibNot proven: 3 of 3 patient groups
- 2025-04-03TruqapCapivasertibConsiderable: 1 of 4 patient groupsNot proven: 3 of 4 patient groups
- 2025-03-20KeytrudaPembrolizumabMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2024-11-07RetsevmoSelpercatinibNot proven
- 2024-05-02OrserduElacestrantConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2024-02-15TrodelvySacituzumab govitecanConsiderable
- 2024-02-06RozlytrekEntrectinibNot proven
- 2023-07-20EnhertuTrastuzumab deruxtecanConsiderable
- 2023-06-15VerzeniosAbemaciclibMinor
- 2023-03-16PhesgoPertuzumab/TrastuzumabMinor
- 2023-03-16PerjetaPertuzumabMinor
- 2023-02-16LynparzaOlaparibMinor
- 2023-02-02EnhertuTrastuzumab deruxtecanConsiderable
- 2023-02-02EnhertuTrastuzumab deruxtecanNon-quantifiable
- 2022-12-15IbrancePalbociclibNot proven
- 2022-10-20VerzeniosAbemaciclibNot proven
- 2022-05-19VerzeniosAbemaciclibMinor: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2022-05-19TrodelvySacituzumab govitecanMajor
- 2022-05-05KeytrudaPembrolizumabConsiderable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2021-09-02TukysaTucatinibConsiderable
- 2021-07-15PhesgoPertuzumab/TrastuzumabNot proven
- 2021-07-15PhesgoPertuzumab/TrastuzumabNot proven
- 2021-02-18RozlytrekEntrectinibNot proven
- 2021-02-18PiqrayAlpelisibNot proven: 3 of 5 patient groupsLesser benefit: 2 of 5 patient groups
- 2020-11-20TalzennaTalazoparibConsiderable
- 2020-09-03VerzeniosAbemaciclibNot proven
- 2020-08-20KisqaliRibociclibMinor: 2 of 2 patient groups
- 2020-08-20KisqaliRibociclibMinor
- 2020-07-02KadcylaTrastuzumab EmtansinMinor
- 2020-05-14NerlynxNeratinibMinor
- 2020-04-02TecentriqAtezolizumabNon-quantifiable
- 2020-04-02VitrakviLarotrectinibNot proven
- 2020-01-16LynparzaOlaparibMinor
- 2019-07-04KisqaliRibociclibNot proven: 5 of 5 patient groups
- 2019-05-02VerzeniosAbemaciclibNot proven
- 2019-05-02VerzeniosAbemaciclibNot proven: 3 of 3 patient groups
- 2019-03-22IbrancePalbociclibNot proven: 2 of 2 patient groups
- 2017-05-18IbrancePalbociclibNot proven
- 2016-02-18PerjetaPertuzumabNot proven
- 2015-01-22HalavenEribulinConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2014-06-19KadcylaTrastuzumab EmtansinConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
- 2013-10-01PerjetaPertuzumabConsiderable: 1 of 3 patient groupsNot proven: 2 of 3 patient groups
Data status: 2026-10-29